Retraction: Calcium channel blockers and risk of breast cancer: A meta-analysis of 17 observational studies (PLoS One (2014) 9:9 (e105801) DOI: 10.1371/journal.pone.0105801);Calcium channel blockers and risk of breast cancer: A meta-analysis of 17 observational studies

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Li, Wen ^a   Shi, Qi ^a   Wang, Weibing ^b   Liu, Jianrong ^a   Li, Qi ^a   Hou, Fenggang ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; NIFEDIPINE; VERAPAMIL; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG USE; FOLLOW UP; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADULT; AGED; BREAST TUMOR; CHEMICALLY INDUCED; FEMALE; HYPERTENSION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RISK;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BREAST NEOPLASMS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DILTIAZEM; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; NIFEDIPINE; ODDS RATIO;

EID: 84906963812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0198220     Document Type: Erratum

References (43)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: a cancer journal for clinicians 62: 10-29.
2. Hunter DJ, Reddy KS (2013) Noncommunicable diseases. New England Journal of Medicine 369: 1336-1343.
3. Quinn M, Allen E (1995) Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. Bmj 311: 1391- 1395.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
5. Chobanian AV (1996) Calcium channel blockers. JAMA: the journal of the American Medical Association 276: 829-830.
6. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, et al. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA: the journal of the American Medical Association 274: 620- 625.
7. Konrad-Dalhoff I, Baunack A, Rämsch K, Ahr G, Kraft H, et al. (1991) Effect of the calcium antagonists nifedipine, nitrendipine, nimodipine and nisoldipine on oesophageal motility in man. European journal of clinical pharmacology 41: 313-316.
8. Pahor M, Guralnik J, Chrischilles EA, Wallace RB (1994) Use of laxative medication in older persons and associations with low serum albumin. Journal of the American Geriatrics Society 42: 50-56.
9. Wagenknecht L, Furberg C, Hammon J, Legault C, Troost B (1995) Surgical bleeding: unexpected effect of a calcium antagonist. BMJ: British Medical Journal 310: 776.
10. Pahor M, Carbonin P, Guralnik J, Havlik R, Furberg C (1996) Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. The Lancet 347: 1061-1065.
11. Stein G, Srivastava MK, Merker H-J, Neubert D (1990) Effects of calcium channel blockers on the development of early rat postimplantation embryos in culture. Archives of toxicology 64: 623-638.
12. Carson DA, Ribeiro JM (1993) Apoptosis and disease. The Lancet 341: 1251- 1254.
13. Pahor M, Guralnik JM, Ferrucci L, Corti M-C, Salive ME, et al. (1996) Calcium-channel blockade and incidence of cancer in aged populations. The Lancet 348: 493-497.
14. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, et al. (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98: 1504-1513.
15. Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. (1998) Cancer risk of hypertensive patients taking calcium antagonists. Journal of hypertension 16: 119-124.
16. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (1997) Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 80: 1438-1447.
17. Li CI, Daling JR, Tang M-TC, Haugen KL, Porter PL, et al. (2013) Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA internal medicine 173: 1629-1637.
18. Meier CR, Derby LE, Jick SS, Jick H (2000) Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Archives of internal medicine 160: 349.
19. Sørensen HT, Olsen JH, Mellemkjær L, Thulstrup AM, Steffensen FH, et al. (2000) Cancer risk and mortality in users of calcium channel blockers. Cancer 89: 165-170.
20. Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE, et al. (1998) Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of US women. Cancer 83: 2003-2007.
21. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, et al. (1998) Calcium channel blockers and the risk of cancer. JAMA: The Journal of the American Medical Association 279: 1000-1004.
22. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, et al. (1997) Calcium-channel blockers and risk of cancer. The Lancet 349: 525-528.
23. Olsen JH, Sørensen HT, Friis S, McLaughlin JK, Steffensen FH, et al. (1997) Cancer risk in users of calcium channel blockers. Hypertension 29: 1091-1094.
24. Knobloch K, Yoon U, Vogt PM (2011) Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. Journal of Cranio-Maxillofacial Surgery 39: 91-92.
25. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine 151: 264-269.
26. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315: 629-634.
27. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2007) Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Statistics in medicine 26: 4544-4562.
28. Duval S, Tweedie R (2000) Trim and Fill: A Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis. Biometrics 56: 455-463.
29. Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA (2004) Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiology and drug safety 13: 581-585.
30. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Nørgaard M, et al. (2006) A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast cancer research and treatment 97: 231-236.
31. Davis S, Mirick DK (2007) Medication use and the risk of breast cancer. European journal of epidemiology 22: 319-325.
32. Assimes TL, Elstein E, Langleben A, Suissa S (2008) Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiology and drug safety 17: 1039-1049.
33. Saltzman BS, Weiss NS, Sieh W, Fitzpatrick AL, McTiernan A, et al. (2013) Use of antihypertensive medications and breast cancer risk. Cancer Causes & Control 24: 365-371.
34. Holmes S, Griffith EJ, Musto G, Minuk GY (2013) Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study. Cancer epidemiology 37: 881-885.
35. Beiderbeck-Noll A, Sturkenboom M, Van Der Linden P, Herings R, Hofman A, et al. (2003) Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. European Journal of Cancer 39: 98-105.
36. Braun S, Boyko V, Behar S, Reicher-Reiss H, Laniado S, et al. (1998) Calcium Channel Blocking Agents and Risk of Cancer in Patients With Coronary Heart Disease 1. Journal of the American College of Cardiology 31: 804-808.
37. Lindberg G, Lindblad U, Löw-Larsen B, Merlo J, Melander A, et al. (2002) Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study. pharmacoepidemiology and drug safety 11: 493-497.
38. Moon D, McCormack D, McDonald D, McFadden D (2013) Pterostilbene induces mitochondrially derived apoptosis in breast cancer cells in vitro. Journal of Surgical Research 180: 208-215.
39. Handayani S (2013) Selaginella Active Fractions Induce Apoptosis on T47D Breast Cancer Cell. Indonesian Journal of Pharmacy 23.
40. Curry MC, Peters AA, Kenny PA, Roberts-Thomson SJ, Monteith GR (2013) Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. Biochemical and biophysical research communications.
41. Das A, Pushparaj C, Herreros J, Nager M, Vilella R, et al. (2013) T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells. Pigment cell & melanoma research 26: 874-885.
42. Jang SJ, Choi HW, Choi DL, Cho S, Rim H-K, et al. (2013) In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers. Bioorganic & medicinal chemistry letters 23: 6656-6662.
43. Altamirano F, Valladares D, Henríquez-Olguín C, Casas M, López JR, et al. (2013) Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice. PloS one 8: e81222.